What are Otezla (apremilast) sales figures?
Otezla sales track the drug’s global revenue, typically reported by the manufacturer in quarterly and annual financial results. The key point for investors and analysts is that revenue trends are driven by ongoing uptake in approved indications (psoriatic arthritis and plaque psoriasis, among others), plus competitive pressure from newer therapies in immune-mediated diseases.
Who sells Otezla and where does revenue show up?
Otezla is marketed and sold by Celgene (part of Bristol Myers Squibb). In practice, Otezla revenue appears in company reporting as part of branded product sales, not as a standalone line in all financial summaries. Those figures are used to gauge growth/decline versus expectations.
Why do Otezla sales change over time?
Sales can move because of:
- Prescribing shifts within dermatology and rheumatology (newer oral drugs and biologics can affect demand).
- Payer coverage and formulary decisions.
- Safety/tolerability perceptions that influence persistence on therapy.
- Patent and exclusivity timelines that affect future generic/biosimilar competitive dynamics (more relevant later than near-term performance).
What do analysts look at when comparing Otezla sales to competitors?
When people search “Otezla sales,” they often want to benchmark it against other treatments in the same spaces (psoriasis, psoriatic arthritis). The comparison is usually framed around:
- Market share trends by mechanism class (oral small molecules vs biologics).
- Uptake in biologic-naive versus biologic-experienced patients.
- Real-world persistence (how long patients stay on treatment).
Where can I find the most reliable Otezla revenue numbers?
For a quick way to locate drug-specific background (including commercial and market context that can help interpret revenue), DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/ (search for Otezla there).
Is there a patent/generic event that could affect future Otezla sales?
Search activity around “Otezla sales” often overlaps with “generic when” questions. Patent and exclusivity status can matter for revenue durability once competition is possible. DrugPatentWatch.com can help you check patent timelines and potential entry risk: https://www.drugpatentwatch.com/
Sources
1. https://www.drugpatentwatch.com/